Semaglutide led a small GLP-1 evidence network in psychiatric populations

A Translational Psychiatry network meta-analysis ranked weekly semaglutide highest for estimated weight reduction among GLP-1 receptor agonists studied in people with obesity and mental illness. The ranking is promising, but the authors explicitly caution that the evidence network was sparse, heterogeneous, and largely indirect.

What evidence was combined

The analysis included nine randomized controlled trials and 595 participants. Their average age was 37.8 years, 55.3% were women, and 83.9% had schizophrenia-spectrum disorders. The treatment network included exenatide, liraglutide, semaglutide, and control groups.

What the analysis found

• Daily liraglutide and weekly semaglutide were both associated with lower body weight than control.
• Semaglutide had the largest estimated effect versus control: standardized mean difference −2.101, with a 95% confidence interval from −2.978 to −1.224.
• Semaglutide was also associated with reductions in BMI, waist circumference, fasting glucose, and HbA1c, alongside more nausea, vomiting, and constipation than control.

A network meta-analysis can compare treatments through a mixture of direct head-to-head evidence and indirect connections through a common comparator. That makes the method useful when head-to-head trials are scarce, but it also makes the certainty of the ranking depend on how connected and consistent the evidence network is.

Clinical context

Weight gain and metabolic risk can complicate treatment for people taking antipsychotic or other psychiatric medicines. These results support further dedicated trials, but medication decisions still need coordinated psychiatric and metabolic care. The analysis does not justify changing psychiatric treatment or starting a GLP-1 drug without a clinician.

The practical takeaway

Semaglutide is the leading signal in this small evidence network—not a settled winner. Larger head-to-head randomized trials with longer follow-up are needed to clarify comparative weight, metabolic, psychiatric, and safety outcomes.